Clearside Biomedical's CMO presented drug development insights at the Edridge Green Lecture, published in Eye journal, focusing on retinal disease trials.
Quiver AI Summary
Clearside Biomedical, Inc., a biopharmaceutical company focused on innovative eye therapy delivery, announced that Dr. Victor Chong, its Chief Medical Officer, presented critical insights into drug development at the Edridge Green Lecture, which was published in the journal Eye. The article discusses clinical trial design and regulatory processes with emphasis on retinal diseases, highlighting recent advancements such as new efficacy endpoints. Dr. Chong emphasized the importance of academic-industry collaborations and case studies from ongoing trials in retinal health. He stated that sharing these insights aims to accelerate the search for effective treatments for retinal diseases. Clearside is known for its suprachoroidal space (SCS) injection platform and its development of therapies like CLS-AX for age-related macular degeneration.
Potential Positives
- Clearside Biomedical's Chief Medical Officer, Dr. Victor Chong, delivered the prestigious Edridge Green Lecture, enhancing the company's visibility and credibility in the field of ophthalmology.
- The publication in a reputable journal, Eye, showcases Clearside's commitment to advancing drug development and regulatory knowledge, potentially attracting interest from industry peers and investors.
- Discussion of innovative clinical trial designs and regulatory expectations reflects Clearside's active role in shaping the future of therapies for retinal diseases, reinforcing its position as a leader in the biopharmaceutical sector.
Potential Negatives
- None
FAQ
What is Clearside Biomedical, Inc. known for?
Clearside Biomedical, Inc. is known for revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).
Who presented at the Edridge Green Lecture?
Dr. Victor Chong, Clearside's Chief Medical Officer, presented critical insights at the prestigious Edridge Green Lecture.
What topics did Dr. Chong cover in his lecture?
Dr. Chong covered clinical trial design, regulatory expectations, and advancements in treating retinal diseases.
What advancements in drug development were highlighted?
Key advancements include new anatomical endpoints and incorporating low-luminance vision as a secondary endpoint in trials.
How does Clearside's SCS Microinjector work?
The SCS Microinjector enables targeted, non-surgical, repeatable procedures for delivering therapies to the eye.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLSD Insider Trading Activity
$CLSD insiders have traded $CLSD stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here's a breakdown of recent trading of $CLSD stock by insiders over the last 6 months:
- NGAI HANG VICTOR CHONG (Chief Medical Officer) has traded it 2 times. They made 2 purchases, buying 60,000 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLSD Hedge Fund Activity
We have seen 17 institutional investors add shares of $CLSD stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 2,465,373 shares (-95.1%) from their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC removed 2,136,000 shares (-100.0%) from their portfolio in Q3 2024
- FIRST MANHATTAN CO. LLC. added 491,142 shares (+280.7%) to their portfolio in Q3 2024
- CARMIGNAC GESTION removed 199,213 shares (-9.3%) from their portfolio in Q3 2024
- GCM GROSVENOR HOLDINGS, LLC added 198,690 shares (+inf%) to their portfolio in Q3 2024
- RENAISSANCE TECHNOLOGIES LLC added 162,200 shares (+27.8%) to their portfolio in Q3 2024
- CASTLEVIEW PARTNERS, LLC removed 161,962 shares (-100.0%) from their portfolio in Q2 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS
), announced today that the official journal of The Royal College of Ophthalmologists,
Eye
, published a summary of critical insights into drug development and regulatory processes based on a presentation at the prestigious annual Edridge Green Lecture by Clearside's Chief Medical Officer and Executive Vice President, Head of Research and Development, Dr. Victor Chong.
The article, which was published in December 2024 by
Eye
and
Nature.com
, provides a comprehensive overview of the intricate processes involved in clinical trial design and regulatory pathways for drug development, with a special focus on retinal diseases.
Dr. Chong's lecture focused on the structure of clinical trials, crucial efficacy and safety endpoints, and the expectations of regulatory agencies like the U.S. Food & Drug Administration. Key recent advancements, such as incorporating low-luminance vision as a secondary endpoint, and case studies from age-related macular degeneration trials, highlight the evolving landscape of drug approvals. The lecture also examined the dynamic landscape of geographic atrophy and diabetic retinopathy trials, emphasizing new anatomical endpoints and innovative drugs. Dr. Chong stressed the value of academic-industry collaborations, citing examples in gene therapy development and novel endpoint measures for retinal dystrophies.
Victor Chong, M.D., MBA, commented, "As a long-time clinician and researcher, it was an honor to be selected to give the Edridge Green Lecture. By highlighting recent advancements, case studies, and regulatory expectations, we can help accelerate the process of finding treatments and cures for serious retinal diseases."
The Edridge Green Lecture is highly significant in the field of ophthalmology and visual sciences and has been delivered at the Royal College of Ophthalmologists Annual Congress since 1956. The Lecture plays a vital role in educating and inspiring the next generation of clinicians and researchers, ultimately contributing to better patient care and outcomes in ophthalmology.
The full publication can be accessed
here
.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS
) to improve patient outcomes. Clearside's SCS injection platform, utilizing the Company's patented SCS Microinjector
, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program,
CLS-AX (axitinib injectable suspension)
, for the treatment of neovascular age-related macular degeneration (wet AMD), recently completed a Phase 2b clinical trial, and planning for a Phase 3 program is underway. Clearside developed and gained approval for its first product,
XIPERE
(triamcinolone acetonide injectable suspension)
for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit
clearsidebio.com
or follow us on
LinkedIn
and
X
.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
Source: Clearside Biomedical, Inc.
